Injury guide

New Symptoms After the Depo Shot

New symptoms after the Depo shot? Get medical advice about what changed.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202617 sources

This may apply to you if

  • Have your shot name and dates ready for a lawyer to review.
  • Have the report that names your meningioma, a tumor in tissue around the brain.
  • If you already have a lawyer, ask whether your claim is eligible for the reported program.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

M. Casey Rodgers · U.S. District Court, Northern District of Florida · United States District Judge

Finding: The August 10, 2026 order describes an agreement for many existing federal claims and separate court procedures for continuing litigation. Ask a lawyer which track applies to you.

Case Management Order No. 14 (opens in a new tab) · Aug 10, 2026 · Checked Oct 3, 2026

Noémie Roland · EPI-PHARE, French National Agency for Medicines and Health Products Safety and French National Health Insurance · First-listed study author

Finding: The 2024 BMJ study found an association between injectable medroxyprogesterone use and meningioma surgery in French health records. A small exposed group and observational design limit what it can show about an individual.

Use of progestogens and the risk of intracranial meningioma: national case-control study (opens in a new tab) · Mar 27, 2024 · Checked Oct 3, 2026

The evidence and its limits

EPI-PHARE · BMJ · 2024

French health-record study of hormone medicines and meningioma surgery

Design:
Case-control
Participants:
108,366 women: 18,061 surgery cases and 90,305 matched controls
Finding:
Injectable medroxyprogesterone acetate use was associated with higher odds of surgery for meningioma; the excess was linked to prolonged use.
Main limitation
Observational French data; only nine exposed cases and eleven exposed controls for this injection. The study does not prove that the shot caused any one person’s tumor or define who qualifies for a claim.

Read the source: French health-record study of hormone medicines and meningioma surgery (opens in a new tab) · Checked Oct 3, 2026

National Health Service (UK) · 2025

NHS patient care guidance, reviewed February 2025

Design:
Other study design
Participants:
Not applicable: public patient guidance, not a study sample
Finding:
The guidance describes symptom assessment and when to seek medical help for possible brain-tumor symptoms.
Main limitation
General UK care guidance; not a Depo causation study, personal diagnosis, MRI screening rule or US service guarantee.

Read the source: NHS patient care guidance, reviewed February 2025 (opens in a new tab) · Checked Oct 3, 2026

The short answer

What is the condition discussed in Depo claims?
The cases allege a tumor called meningioma inside the skull. Symptoms alone do not show that you have this tumor. [1]
When should I seek help for symptoms?
Get urgent help for a first seizure or a sudden, very painful headache. Tell a doctor if other symptoms last or get worse. Do not put off care for a claim. [17]
How are symptoms diagnosed and treated?
A clinician can assess the problem and decide which tests are needed. A scan or referral is part of an evaluation, not proof that the shot caused a tumor. [17]
What does research establish about these symptoms?
The French study looked at surgery for this tumor. It did not test every shot user with symptoms. It cannot tell you what caused your headache. [9]

What rules a case out

Not covered by this case

  • Symptoms or shot use alone do not prove a meningioma claim.
  • A study association does not establish the cause of your own tumor.
  • Care guidance does not set universal scan, program or firm acceptance rules.

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

When it fits this case

  • Have your shot name and dates ready for a lawyer to review.
  • Have the report that names your meningioma, a tumor in tissue around the brain.
  • If you already have a lawyer, ask whether your claim is eligible for the reported program.

New symptoms after the Depo shot? Get medical advice about what changed. Symptoms do not diagnose a tumor. Keep your care notes and ask a lawyer about a claim only with your own history in view.

What is the condition discussed in Depo claims?

The cases allege a tumor called meningioma inside the skull. Symptoms alone do not show that you have this tumor.

A symptom is what you experience; a diagnosis names the condition the team finds. Tell the clinician what you notice before trying to assign it to a tumor. Ask it to explain any term in a report that you do not understand.

A record may describe a possible finding rather than a final diagnosis. Ask the team what has been confirmed and what remains to be checked. Do not change an uncertain report into a definite diagnosis on an intake form.

When should I seek help for symptoms?

Get urgent help for a first seizure or a sudden, very painful headache. Tell a doctor if other symptoms last or get worse. Do not put off care for a claim.

The UK NHS guide treats those sudden events as emergencies. Use the emergency service where you are, rather than the UK contact number in that guide. This is a reason to seek care, not proof of a Depo-related tumor.

Tell the care team when the symptoms began, what they feel like and whether they are changing. Ask what to do while waiting for a visit. If you help another person, describe what you observed and separate it from what that person told you.

How are symptoms diagnosed and treated?

A clinician can assess the problem and decide which tests are needed. A scan or referral is part of an evaluation, not proof that the shot caused a tumor.

NHS guidance describes checks of vision, balance and memory, with a possible scan or specialist referral. That is a general UK care pathway. It does not promise the same tests, timing or referral rules for every US patient.

Ask which test is being proposed, what question it may answer and how results will reach you. Request instructions if the symptoms change before the test. A care plan should come from the team managing your health, not from a legal advertisement.

What does research establish about these symptoms?

The French study looked at surgery for this tumor. It did not test every shot user with symptoms. It cannot tell you what caused your headache.

It was a study of health records, not a trial that assigned the shot. The injection-exposed group was small. The observed link does not supply a personal probability or prove that a symptom came from the drug.

The FDA label tells clinicians to watch for signs of meningioma. It also tells them to stop Depo-Provera CI if the tumor is diagnosed. Ask the prescribing clinician how the warning applies to your care and next dose.

Who can ask about a claim after symptoms appear?

Show a lawyer your health and shot records. Symptoms alone do not prove that you have this tumor. Ask what the firm needs to check your claim.

The court describes claims alleging this tumor after use of branded or generic products. It also addresses future-filed cases. Neither the court program nor a legal website tells you whether your individual claim is sound.

Say if you already have a lawyer or signed agreement. Ask what medical record is needed and which filing deadline applies. Do not wait for a hoped-for payment or assume that a program cutoff ends every claim option.

What records should I keep about symptoms?

Keep a dated account of what changed and the care you sought. Save reports you receive and ask the provider about missing covered records.

Write the start date as accurately as you can. Note changes in work, vision, sleep or daily tasks in your own words. Include the dates of the shots and other medicines, and mark dates you do not recall. Your notes should reflect your experience, not match an ad.

Ask who will receive a medical file before sending it to a legal service. Read the scope of any permission. Also request written fee and expense terms, including costs that may be owed without a win; no specific firm’s price is established by a model fee rule.

Scientific evidence for this case

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Questions about this guide

I have headaches after years of Depo-Provera. Should I be worried?

It depends on the headache and your other symptoms. The National Cancer Institute lists headaches, seizures, confusion, and vision, hearing, or smell changes as possible meningioma symptoms. Bring new or worsening symptoms to your clinician.

Source: National Cancer Institute: Meningioma · as of Oct 7, 2026

Can Depo-Provera meningioma cause seizures?

It depends. Ask your treating clinician about symptoms, testing, or medication changes. The FDA label says to monitor for signs and symptoms of meningioma and to discontinue Depo-Provera CI if a meningioma is diagnosed. A claim page cannot diagnose you or decide your medical care.

Source: FDA Depo-Provera CI label, revised December 2025 · as of Oct 7, 2026

What if my symptoms are mild — do I still have a case?

Yes. Even mild symptoms with a documented meningioma diagnosis are sufficient. Watchful-waiting cases (where the meningioma is monitored but not surgically removed) are compensable. You face ongoing medical monitoring costs, anxiety, quality-of-life impacts, and the risk that the tumor will grow and require future intervention.

Sources

  1. Court order 14: settlement and ongoing casesCourt order 14: settlement and ongoing cases · court
  2. JPML pending cases report, October 1, 2026JPML pending cases report, October 1, 2026 · court
  3. FDA Depo-Provera CI label, December 2025FDA Depo-Provera CI label, December 2025 · regulator
  4. National Cancer Institute: meningiomaNational Cancer Institute: meningioma · regulator
  5. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  6. Medical record access: 45 CFR 164.524Medical record access: 45 CFR 164.524 · regulator
  7. SDNY court guide: filing time limitsSDNY court guide: filing time limits · court
  8. Court common-benefit fee order 2Court common-benefit fee order 2 · court
  9. BMJ 2024 original author abstract via PubMedBMJ 2024 original author abstract via PubMed · study
  10. Medroxyprogesterone Acetate and Meningioma: A Global IssueFrontiers in Global Womens Health · 2025 · study
  11. Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial MeningiomaThe BMJ · 2024 · study
  12. The Association between Medroxyprogesterone Acetate Exposure and MeningiomaCancers · 2024 · study
  13. Pfizer Reaches Agreement in Principle to Resolve Federal Depo-Provera MDLlaw360.com · Jun 15, 2026 · court
  14. JAMA Network Open Study Reports 4.5x Meningioma Risk with Medroxyprogesteronepubmed.ncbi.nlm.nih.gov · Jul 1, 2026 · study
  15. On June 15, 2026, MDL 3140 (N.D. Fla.) Leadership Counsel announced a settlement with the Pfizer defendants of a majority of the claims in the MDL and New York state court over Depo-Provera meningioma claims (Case Management Order No. 12, filed July 27, 2026). Financial terms NOT disclosed; eligibility and compensation amounts not released; deal pending finalization at the time (Case Management Order No. 14, filed Aug. 10, 2026, later described a settlement agreement dated July 22, 2026 and states no compensation amounts). The JPML reported 5,830 actions pending in MDL 3140 on July 1, 2026 and 6,412 on October 1, 2026.flnd.uscourts.gov · Jun 15, 2026 · court
  16. Settlement in principle announced; docket had grown +1,739 filings (+46%) in the single preceding month — the leading-indicator pattern.jpml.uscourts.gov · Jun 15, 2026 · court
  17. NHS: non-cancerous brain tumor guidance

Checked against 15 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026